3-5, Impasse Reille
Paris 75014
France
https://www.neovacs.com
Sector(s):
Industry:
Full-time employees: 23
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Hugo Brugiere M.Sc. | Chairman, GM & CEO | 85k | N/A | N/A |
Prof. Daniel Zagury | Founder, Chairman of Scientific Research Committee & Director | 6k | N/A | N/A |
Mr. Vincent Serra Ph.D. | Scientific & Operational Director | 188.8k | N/A | 1970 |
Mr. Alexandre Courtoux | Administrative & Financial Director | N/A | N/A | N/A |
Charlene Masson | Corporate Communication & Investor Relations | N/A | N/A | N/A |
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company was founded in 1993 and is based in Paris, France.
NEOVACS SA NEOVACS ORD SHS’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.